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Abstract
Background: Intracerebral hemorrhage (ICH) is a potentially fatal stroke subtype accounting for 10–15 % of all strokes.
Despite neurosurgical intervention and supportive care, the 30-day mortality rate remains 30–50 % with ICH survivors
frequently displaying neurological impairment and requiring long-term assisted care. Although accumulating evidence
demonstrates the role of neuroinflammation in secondary brain injury and delayed fatality after ICH, the molecular
regulators of neuroinflammation remain poorly defined after ICH.
Methods: In the present study, ICH was induced in CD1 male mice by collagenase injection method and given the
emerging role of TSPO (18-kDa translocator protein) in neuroinflammation, immunofluorescence staining of brain
sections was performed to characterize the temporal expression pattern and cellular and subcellular localization of
TSPO after ICH. Further, both genetic and pharmacological studies were employed to assess the functional role of
TSPO in neuroinflammation.
Results: The expression of TSPO was found to be increased in the peri-hematomal brain region 1 to 7 days
post-injury, peaking on day 3 to day 5 in comparison to sham. Further, the TSPO expression was mostly
observed in microglia/macrophages, the inflammatory cells of the central nervous system, suggesting an
unexplored role of TSPO in neuroinflammatory responses after ICH. Further, the subcellular localization studies revealed
prominent perinuclear expression of TSPO after ICH. Moreover, both genetic and pharmacological studies revealed a
regulatory role of TSPO in the release of pro-inflammatory cytokines in a macrophage cell line, RAW 264.7.
Conclusions: Altogether, the data suggest that TSPO induction after ICH could be an intrinsic mechanism to prevent
an exacerbated inflammatory response and raise the possibility of targeting TSPO for the attenuation of secondary
brain injury after ICH.
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Background
Intracerebral hemorrhage (ICH) is a common and often a
fatal stroke subtype that accounts for 10–15 % of all stroke
events [1]. In-hospital rates of mortality and patient dis-
ability following ICH are 40 and 80 % respectively [2] and
the 1-month mortality rate is 30–50 % [3, 4]. In addition,
a vast majority of ICH survivors do not regain their inde-
pendence within 6 months of symptom onset and at
6 months only 20 % achieve independence in their daily
lives [4, 5]. Despite recent advances in preclinical research,
there is no effective treatment for ICH. Notably, the
current treatment options are largely limited to providing
mechanical ventilation and supportive care. The need for
new therapeutic approaches for ICH has prompted a
search for the molecular and cellular mechanisms that
underlie brain damage after ICH.
TSPO is an 18-kDa trans-membrane protein of 169
amino acids, found primarily in the mitochondrial outer
membrane [6]. TSPO was first identified as a diazepam-
binding protein found in peripheral tissues; hence the
previous denomination as peripheral-type benzodiazep-
ine receptor [7, 8]. It is found in most species from bac-
teria to humans and the cDNA encoding TSPO has
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been cloned from various species such as rodents, bo-
vines, and humans [9–13] among which there is an 80 %
sequence homology [6]. TSPO has been implicated in
many cellular processes including cell proliferation and
differentiation, apoptosis, immunomodulation, tetrapyr-
role biosynthesis, oxidative stress, steroid biosynthesis,
and mitochondrial physiology [14–17]. In particular,
TSPO was thought to be required and essential for the
translocation of cholesterol from the outer mitochon-
drial membrane to the inner mitochondrial membrane,
a limiting step for steroidogenesis [15, 18–20]. How-
ever, recent studies demonstrate that knockdown of
TSPO in different cell types had no effect on viability
and more importantly, that global TSPO knockout mice
were viable and exhibited unaltered steroidogenesis
[21–23], suggesting an elusive and conflicting role of
TSPO in mammalian cells.
In the normal brain, TSPO expression is low, and it is
found mainly in glia and at very low levels in neurons
[8, 24–26]. However upon brain injury, augmented ex-
pression of TSPO is observed in activated glial cells
[27–31] and serves as a biomarker for disease activity
in Alzheimer’s and Parkinson’s disease [32, 33]. Synthetic
ligands to TSPO are also investigated as therapeutic
agents for various CNS disorders [34]. ICH results in both
primary and secondary brain insults, and neuroinflamma-
tion characterized by glial activation is regarded as a major
component of secondary brain injury mechanisms after
ICH. However, the molecular expression and the func-
tional role of TSPO after hemorrhagic brain injury have
not been studied previously. The purpose of this study
was to explore the temporal expression pattern and
characterize the cellular localization of TSPO after ICH.
Methods
ICH
Animal studies were reviewed and approved by the
Committee on Animal Use for Research and Education
at Augusta University, in compliance with NIH and
USDA guidelines. Male CD-1 mice (8–10 weeks old;
Charles River) were anesthetized with an intraperito-
neal injection of ketamine and xylazine and positioned
prone in a stereotaxic head frame (Stoelting, WI, USA).
A small animal temperature controller (David Kopf
Instruments, USA) was used to maintain the body
temperature at 37 ± 0.5 °C throughout surgery. With a
high-speed dental drill (Dremel, USA), a 0.5-mm burr hole
was made 2.2 mm lateral to the bregma, taking care not to
damage the underlying dura. A 26-G Hamilton syringe
containing 0.04 U of bacterial type IV collagenase (Sigma,
St. Louis, MO, USA) in 0.5-μl saline was inserted with
stereotaxic guidance 3.0 mm into the left striatum to in-
duce spontaneous ICH [35, 36]. After removal of the nee-
dle, the burr hole was sealed with bone wax and the
incision was surgically stapled. Sham animals underwent
the same surgical procedure, but only a saline injection
(0.5 μl) was performed. Mice were maintained at 37 °C
until recovery.
Immunohistochemistry
Deeply anesthetized mice were transcardially perfused with
0.1-M phosphate-buffered saline (pH 7.4; PBS), followed
by 4 % paraformaldehyde in PBS. The brains were post-
fixed overnight in 4 % paraformaldehyde and cryoprotected
in 30 % sucrose at 4 °C until the brains were permeated.
They were snap-frozen and sectioned at 25 μm using a
cryostat. The coronal sections mounted on glass slides
were incubated at 20 °C with 10 % normal donkey serum
in PBS containing 0.4 % Triton X-100 for 1 h, followed by
incubation with primary antibodies [Iba1 (ionized calcium
binding adaptor molecule; 1:100; goat polyclonal; Abcam,
MA, USA), TSPO (1:250; rabbit monoclonal; Abcam,
MA, USA), glial fibrillary acidic protein (GFAP, 1:1000;
goat polyclonal; Abcam, MA, USA), NeuN (1:100; mouse
monoclonal; EMD Millipore, MA, USA), CD16/32 (1:100;
rat monoclonal; BD Biosciences, CA, USA), CD206 (1:100;
mouse monoclonal; BD Biosciences, CA, USA), and prolif-
erating cell nuclear antigen (PCNA, 1:100; mouse monoclo-
nal ; Cell Signaling, MA, USA)] at 4 °C for 24 h in 0.2 %
Triton X-100 containing PBS. Sections were washed and
incubated with appropriate Alexa Fluor-tagged secondary
antibody (1:1000; Invitrogen/Life Technologies, USA; Alexa
Fluor 594 conjugated donkey anti-Rat IgG, Alexa Fluor 594
or Alexa Fluor 488 conjugated donkey anti-Rabbit IgG,
Alexa Fluor 594 or Alexa Fluor 488 conjugated donkey
anti-Mouse IgG, and Alexa Fluor 488 conjugated donkey
anti-Goat IgG) at room temperature for 1 h in 0.2 % Triton
X-100 containing PBS. After washing, the sections were
cover slipped with a mounting media containing DAPI
(DAPI-Fluoromount-G; SouthernBiotech, AL, USA), a nu-
clear stain. Immunofluorescence was determined using a
Zeiss LSM510 Meta confocal laser microscope and cellular
colocalization was determined, as described earlier [37].
We analyzed 3 non-consecutive sections per animal and a
minimum of 3–5 random fields around the hematoma. The
fluorescence intensity of immunoreactivity and the number
of immunopositive cells were estimated using ImageJ soft-
ware (NIH, USA). The number of immunoreactive cells per
mouse were quantified (3–5 fields per section and 3 sec-
tions per mouse, n = 3 mice/group) and averaged as positive
cells per 0.1 mm2 in the peri-hematomal brain region.
Quantitative assessment of colocalization between TSPO
and CD16/32 or CD206 fluorescent signals was performed
by calculating the overlap coefficient (ranging from 0 %;
minimum colocalization to 100 %; maximum colocali-
zation) using the Zeiss Zen2009 (NY, USA) software.
An average of 10–15 cells were analyzed per section (3
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sections per mouse; n = 3 mice/group) and overlap co-
efficient was calculated.
Cell culture and enzyme-linked immunoassay (ELISA)
The mouse macrophage cell line, RAW 264.7 purchased
from ATCC (American Type Culture Collection), was
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 5 % fetal bovine serum and 5 % bovine
growth serum, 5 % CO2, and 100 % humidity. Cells were
added to tissue culture plates, allowed to adhere overnight,
and then stimulated with hemin (30 μM). TSPO agonist or
antagonist was added 1 h prior to hemin addition, and the
hemin treatment was conducted for 18 h in the presence
of TSPO agonist or antagonist and the supernatant was
collected. The release of pro-inflammatory cytokines such
as (tumor necrosis factor-α) TNF-α and (interleukin-6) IL-
6 into the supernatant was estimated using ELISA as per
manufacturer’s instructions. (RayBiotech, Inc., Norcross,
GA, USA). Briefly, pre-coated 96-well ELISA plates for
different captured antibodies were incubated overnight at
4 °C with cell culture supernatant and different concen-
trations of standard protein, 100 μl per well. Unbound
materials were washed out, and biotinylated respective
anti-cytokine detection antibody was added to each well.
The plates were incubated for 1 h at room temperature.
After washing, 100 μl of streptavidin-HRP conjugate was
added to the wells and incubation was continued for an-
other 45 min at room temperature. After washing, color
development was performed by incubation with substrate
solution. After adding stop solution, the optical density at
450 nm was determined for each well using a microtiter




Fig. 1 Microglial/macrophage activation and ICH. Brain sections were immunostained for Iba1 (a) as described in the “Methods” section. After
counter staining the sections with DAPI, the staining was analyzed using confocal microscopy. ICH remarkably induced microglial/macrophage
activation as evidenced by cellular hypertrophy with enhanced Iba1 staining. Scale bar = 20 μm n = 3–6/group. b The average number of
Iba1-positive cells per 0.1 mm2 in the ipsilateral striatum. c The fluorescence intensity quantification of Iba1 immunoreactivity using ImageJ (NIH, USA).
*p < 0.05, **p < 0.01, ***p < 0.001 vs. sham
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the samples were determined in comparison to the re-
spective standard concentration curve.
Genetic knockdown of TSPO
RAW 264.7 cells were transfected with either control
siRNA (ON-TARGETplus Non-targeting Pool; GE Dhar-
macon) or TSPO siRNA (SMARTpool: ON-TARGETplus
TSPO siRNA; GE Dharmacon). Briefly, the cells were
plated overnight and transfected with control or TSPO
siRNA using HiPerFect Transfection Reagent (QIAGEN)
according to manufacturer’s instructions. Target gene
knockdown was verified 48-h post-transfection by qRT-
PCR. To accomplish this, total RNA was isolated (SV
RNA Isolation System, Promega), and quantitative RT-
PCR was performed on a Cepheid SmartCycler II using
a SuperScript III Platinum SYBR Green One-Step RT-
PCR kit (Invitrogen, Carlsbad, CA, USA). Primers were as
follows: TSPO (5′AGAAACCCTCTTGGCATCCG3′(F),
5′ GCCATACCCCATGGCTGAATA 3′(R) and RPS3: (FP
5′-AATGAACCGAAGCACACCATA-3′; RP 5′-ATCAG
AGAGTTGACCGCAGTT-3′). Product specificity was
confirmed by melting curve analysis and gene expression
levels were quantified using a cDNA standard curve. Data
were normalized to RPS3, a housekeeping gene that was
unaffected by the experimental conditions.
Statistical analysis
The data were analyzed using one-way analysis of vari-
ance followed by Student-Newman-Keuls post hoc test
and were expressed as mean ± SE. A p value of <0.05




Fig. 2 TSPO expression and ICH. a Representative confocal images demonstrating the temporal expression pattern of TSPO immunostaining in
the brain tissue of ICH or sham. The confocal images were obtained from the peri-hematomal brain area of ICH 1–7 days post-injury or from the
comparable brain region of sham. ICH remarkably augmented TSPO expression. Scale bar = 20 μm; n = 4–6/group. b The low magnification image
depicting the profound induction of TSPO in the peri-hematomal brain region 5 days post-ICH or sham. c The average number of TSPO-positive
cells per 0.1 mm2 in the ipsilateral striatum. d The fluorescence intensity quantification of TSPO immunoreactivity using ImageJ (NIH, USA).
*p < 0.05, **p < 0.01, ***p < 0.001 vs. sham
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Results
Temporal expression pattern of TSPO after ICH
Microglia are believed to be the first non-neuronal cells
to react to a brain injury and are regarded as the major
source of expression of pro-inflammatory cytokines after
ICH [38]. Given the emerging role of TSPO in neuroin-
flammation, our goal was to characterize the immune re-
sponse 1 to 7 days post-hemorrhagic injury because the
kinetics of cytokine expression within the first week after
experimental ICH is quite dynamic. In addition, important
clinical sequelae begin to appear within the first 7-day
post-ICH [39]. We found a very prominent microglia/
macrophage activation at day 1 and it peaked at 3 to 5 days
post-ICH as evidenced by a significant induction in both
Iba1 (microglia/macrophage marker) immunofluorescence
intensity and the number of Iba1-immunoreactive cells
around the hematoma in comparison to sham (Fig. 1a–c).
Notably, consistent with the previous reports [40, 41],
Iba1-positive cells in the peri-hematomal area after ICH
predominantly exhibited activated/reactive morphology
with hypertrophic cell body and short processes in com-
parison to the ramified morphology observed in sham-
injured mice (Fig. 1a). Notably, there was approximately
an 8-fold increase (p < 0.001) in the number of Iba1-
positive cells and Iba1 immunofluorescence intensity
(p < 0.001) on day 3 and day 5, post-ICH in comparison
to sham (Fig. 1b, c). However, it is known that Iba1 rec-
ognizes both microglia and macrophages, therefore the
prominent induction in Iba1-positive cells after ICH
could be either due to the proliferation and/or migration
of microglia or due to the infiltration of macrophages after
a brain injury. Furthermore, a week after ICH, microglia/
macrophage activation tended to reduce; however, it did
not reach sham levels (Fig 1a–c), suggesting a prolonged
activation of microglia/macrophage after ICH. To evaluate
TSPO expression after ICH, we performed immunofluor-
escence staining of brain sections acquired at different
time points after surgery. TSPO was expressed at low
levels in sham-operated mice as assessed by immunohisto-
chemistry (Fig. 2) and no TSPO immunoreactivity was ob-
served in the contralateral hemisphere (data not shown).
In contrast, TSPO induction was observed in the peri-
hematomal brain region 1 to 7 days post-injury with a
remarkable up regulation observed on day 3 and day 5
post-injury (Fig. 2a, c, d). The quantification of the number
of TSPO-immunoreactive cells and immunofluorescence
A
B
Fig. 3 Cellular localization of TSPO. Double immunolabeling of brain sections from sham/ICH mice were performed for a TSPO and NeuN
and b TSPO and GFAP 5 days post-surgery. TSPO expression was absent in both NeuN-positive and GFAP-positive cells after ICH. Scale
bar = 20 μm; n = 3/group
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intensity analysis together confirmed a significant induction
of TSPO expression on day 3 and day 5 in comparison to
sham (Fig. 2c, d). Along these lines, there was approxi-
mately a 6-fold increase (p < 0.001) in TSPO immunoreac-
tivity on day 3 and day 5 post-ICH in comparison to sham
(Fig. 2c, d).
Cellular and subcellular localization of TSPO expression
after ICH
To establish the cellular localization of TSPO after ICH,
we employed double immunohistochemical labeling. TSPO
expression was not found in GFAP- and NeuN-positive
cells suggesting the absence of TSPO expression in astro-
cytes and neurons, respectively, after ICH (Fig. 3). In con-
trast, a remarkable colocalization of TSPO was observed in
Iba1-positive cells, suggesting that TSPO-expressing cells
after ICH are mostly microglia/macrophages, the inflam-
matory cells of CNS (Fig. 4). Notably, microglia/macro-
phages exhibited polarization after ICH and the analysis of
immunopositive cell number and fluorescence intensity to-
gether revealed a significant induction of pro-inflammatory
M1 microglia/macrophage marker, CD16/32 expression in
the peri-hematomal brain region at 3 to 7 days post-injury,
peaking on day 5, in comparison to sham (Fig. 5a–c).
Further, CD16/32 expression was mostly confined to
Iba1-positive cells after ICH (Fig. 5d) and the number of
CD16/32-positive cells increased 6- and 10-fold (p < 0.001)
on day 3 and day 5 post-ICH, respectively, in comparison
to sham (Fig. 5b). Of note, the expression of anti-
inflammatory M2 microglia/macrophage marker, CD206,
was observed mostly on day 1 and day 3 post-ICH, with a
peak expression observed on day 3 (Fig. 6a–c). There was a
6-fold increase (p < 0.001) in CD206-positive cells on day 3
post-ICH in comparison to sham (Fig. 6b) and the expres-
sion of CD206 colocalized with Iba1 (Fig. 6d). Moreover,
both CD16/32 - and CD206-positive cells co-expressed
TSPO further emphasizing the role of TSPO in neuroin-
flammatory responses after ICH (Fig. 7a, b). Quantitative
colocalization analysis of images revealed a percentage of
colocalization of 58.06 ± 2.3 and 46.97 ± 1.7 % between
TSPO and CD16/32 or CD206, respectively, post-ICH
(Fig. 7c, d). Though there was a difference in overlap of
11.09 % between the two, it was not statistically significant
(data not shown). Furthermore, the subcellular localization
of TSPO revealed prominent perinuclear expression of
TSPO upon colocalization with PCNA, a nuclear marker
of proliferating cells (Fig. 8).
Pharmacological and genetic modulation of TSPO
signaling significantly alters the release of
pro-inflammatory cytokines
To establish the functional role of TSPO in microglial/
macrophage activation, we studied whether a TSPO
agonist, Ro5-4864, is able to modulate hemin-mediated
inflammatory reaction. Hemin is a metabolite, which accu-
mulates at high concentration in intracranial hematomas
Fig. 4 TSPO expression in microglia/macrophage. Double immunolabeling of brain sections were performed for TSPO and Iba1 5 days
post-injury. A very prominent expression of TSPO was observed in Iba1-positive cells and the lowest panel depicts high magnification
image. Scale bar = 20 μm; n = 3/group
Bonsack et al. Journal of Neuroinflammation  (2016) 13:151 Page 6 of 14
and is known to induce microglial activation via TLR-4
(Toll-like receptor-4) signaling mechanism [42]. Hemin
treatment significantly augmented the release of pro-
inflammatory cytokines TNF-α and IL-6 from murine
macrophage cell line, RAW 264.7 cells, as evidenced by
ELISA, whereas the incubation of cells with TSPO agonist,
Ro5-4864, attenuated hemin-induced release of both TNF-
α and IL-6 (Fig. 9). Along these lines, Ro5-4864 (5 and
10 μM) significantly reduced hemin-induced release of
TNF-α by 87 and 97 %, respectively (Fig. 9a; p < 0.05 vs. he-
min alone), and IL-6 by 52 and 79 %, respectively (Fig. 9b;
p < 0.001 vs. hemin alone). Further, TSPO antagonist
(PK11195) did not reduce hemin-induced TNF-α secretion
(data not shown). To validate this further, we performed
siRNA-mediated genetic knockdown of TSPO expression
in RAW 264.7 cells and examined the inflammatory re-
sponse. Notably, silencing of TSPO expression in RAW
264.7 cells by siRNA significantly reduced the TSPO ex-
pression by 52.6 % (Fig. 10a; p < 0.001 vs. control) and aug-
mented hemin-induced release of TNF-α and IL-6 by 2-
fold in comparison to controls (Fig. 10b, c; p < 0.01 vs.
hemin-treated control). Altogether, the data derived from
both pharmacological and genetic studies suggest that
TSPO may serve as a negative regulator of inflammation
after ICH.
Discussion
Intracerebral hemorrhage (ICH) is a stroke subtype result-
ing from the spontaneous extravasation of blood into the
brain parenchyma. Though chronic hypertension, amyloid
angiopathy, and advanced age are recognized as the prom-
inent risk factors of ICH, the risk factors also include but
not limited to ethnic differences and lifestyle factors such





Fig. 5 CD16/32 expression and ICH. a Immunofluorescent labeling was performed for CD16/32 on the brain sections from sham or 1–7 days
post-ICH and was analyzed using confocal microscopy after counter staining the sections with DAPI. b The average number of CD16/32-positive
cells per 0.1 mm2 in the ipsilateral striatum. c The fluorescence intensity quantification of CD16/32 immunoreactivity using ImageJ (NIH, USA).
*p < 0.05, ***p < 0.001 vs. sham. d Brain sections from sham/ICH mice were immunolabeled for CD16/32 and Iba1, 5 days post-surgery. CD16/
32 expression was mostly observed in Iba1-positive microglia/macrophage after ICH. Scale bar = 20 μm; n = 3–4/group
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worldwide incidence of ICH is 2 million cases per year [2],
with approximately 120,000 cases per year in the USA
[44–46]. However, the incidence is expected to have dou-
bled by 2050 [39] due to aging and the spreading use of
anticoagulants [47]. Though ICH is a major public health
problem, no effective medical or surgical therapy has been
firmly established. Given the critical role of microglia/
macrophage-mediated inflammation in ICH-induced sec-
ondary brain injury, a thorough understanding of the mo-
lecular regulators of inflammation in hemorrhagic brain
injury is critical. This study identifies for the first time the
microglia/macrophage expression of TSPO and the exist-
ence of M1 and M2 microglia/macrophage phenotypes in
a preclinical model of ICH.
Secondary inflammatory damage to brain tissue has
emerged as a common link between different types of
central nervous system disorders [48–51]. ICH results in
both primary and secondary brain insults, and several
clinical and preclinical studies have suggested a significant
contribution of neuroinflammation to the pathophysiology
of ICH [47, 52, 53]. Notably, activated microglia and newly
recruited peripheral macrophages are regarded as the key
cellular regulators of neuroinflammation after ICH based
on their local release of cytokines, chemokines, prosta-
glandins, proteases, ferrous iron, and other immunoactive
molecules [52, 54, 55]. Under normal conditions, micro-
glia retain a relative quiescent phenotype for constant
monitoring of the brain parenchyma [56]. As influenced
by their environment, both resident microglia and per-
ipheral macrophages assume pro-inflammatory M1
and anti-inflammatory M2 phenotypes. M1 polarized




Fig. 6 CD206 expression and ICH. a Brain sections were immunostained for CD206, as described in the “Methods” section. Staining was analyzed
using confocal microscopy and images were obtained from the peri-hematomal brain tissue of ICH 1–7 days post-injury or from the comparable
brain region of sham. b The average number of CD206-positive cells per 0.1 mm2 in the ipsilateral striatum. c The fluorescence intensity
quantification of CD16/32 immunoreactivity using ImageJ (NIH, USA). *p < 0.05, ***p < 0.001 vs. sham. d Representative confocal images
demonstrating the dual immunolabeling of brain sections for CD206 and Iba1 on day 3 post sham/ICH. Scale bar = 20 μm; n = 3–7/group
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pro-inflammatory cytokines such as TNF-α, IL-1β, and
pro-oxidant enzymes such as inducible nitric oxide
synthase [57, 58]. In contrast, M2-polarized microglia/
macrophages produce neurotrophic factors and have
been associated with regenerative effects after brain injury
[59]. However, the microglia/macrophage polarization
after ICH is largely uncharacterized and herein we dem-
onstrate for the first time the temporal pattern of micro-
glia/macrophage polarization after ICH.
The inflammatory response to ICH is characterized by a
rapid activation of resident microglia within minutes after
the onset of ICH and the activated microglia/macrophage
are found in and around the hematoma [52, 54, 60]. The
early response of microglia/macrophage to ICH suggests
that components of the hematoma may trigger microglial
activation. Consistently, the hematoma components such
as erythrocytes and its lysed products (Hb, heme, and
iron), thrombin (blood coagulation factor), and comple-
ments are capable of activating microglia/macrophages
[61–64]. However, the precise molecular mechanism of
microglia/macrophage activation after ICH remains un-
clear. Further, hemin, a hemoglobin metabolite which
accumulates at high concentration in intracranial he-
matomas [65], can induce inflammatory brain injury
after ICH [64]. Altogether, inflammatory signaling trig-





Fig. 7 TSPO expression in M1 and M2 microglia/macrophage. Double immunolabeling of brain sections from sham/ICH mice were performed
for a TSPO and CD 16/32 and b TSPO and CD206 on day 5 and day 3 post-surgery, respectively. The lowest panel depicts respective high
magnification image. Scale bar = 20 μm. The percentage of colocalization between TSPO and CD16/32 (c) or CD206 (d) as assessed by calculating the
overlap coefficient as described in the “Methods” section. **p < 0.01, ***p < 0.001 vs. sham
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activation, peripheral inflammatory cell infiltration, and
release of pro-inflammatory mediators, eventually result-
ing in massive brain cell death and neurological deficits.
However, intrinsic regulators of microglia/macrophage ac-
tivation after ICH remain largely uncharacterized.
Herein, we demonstrate for the first time that the TSPO
expression is elevated after ICH and the peak expression is
observed on day 3 to day 5 post-ICH, the time point that
exhibits very prominent microglia/macrophage activation.
Furthermore, TSPO expression was observed mostly in
the Iba1-positive microglia or macrophage whereas TSPO
expression was not observed in either GFAP- or NeuN-
positive cells, making TSPO a suitable molecular target
to modulate microglia/macrophage functions after ICH.
Furthermore, microglia/macrophage exhibited both pro-
inflammatory M1 and anti-inflammatory M2 phenotypes
after ICH. The expression of M1 cell surface marker
CD16/32 is found to be prolonged after ICH in contrast
to an early occurrence of M2, cell surface marker, CD206
suggesting a possible role of pro-inflammatory M1 micro-
glia/macrophage in ICH-mediated both acute and long-
term neurological deficits. Further, the early occurrence of
Fig. 8 Subcellular localization of TSPO. Dual-label fluorescence immunohistochemistry was performed for proliferating cell nuclear antigen (PCNA),
a cellular proliferation marker, and TSPO, in sham-operated mice or at 5 days post-ICH and prominent perinuclear expression of TSPO was
observed after ICH and the lowest panel depicts high magnification image. Scale bar = 20 μm
A B
Fig. 9 Ro5-4864-attenuated hemin-induced release of TNF-α and IL-6. RAW 264.7 cells were plated overnight and TSPO agonist, Ro5-4864, was
added 1 h prior to hemin (30 μM) addition and the hemin treatment was conducted in the presence of Ro5-4864 and the supernatant was
collected. The release of TNF-α (a) and IL-6 (b) into the supernatant was estimated using ELISA as per manufacturer’s instructions. (RayBiotech,
Inc., Norcross, GA, USA). Ro5-4864 treatment significantly attenuated the hemin-induced release of TNF-α and IL-6. n = 4–9; *p < 0.05, ***p < 0.001
vs. hemin alone
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CD206-positive M2 microglia/macrophage after ICH
could be an intrinsic mechanism to remove cellular debris
derived from hematoma or to restore brain homeostasis.
More importantly, the expression of TSPO in both M1
and M2 microglia/macrophage as demonstrated herein
suggests an unexplored role of TSPO in neuroinflam-
matory responses after ICH. In addition, a TSPO agon-
ist attenuated hemin-mediated release of TNF-α and
IL-6 from RAW 264.7 cells, suggesting that TSPO can
be therapeutically targeted to attenuate neuroinflamma-
tory response after ICH and this was further supported
by the genetic knockdown studies. However, further
studies are required to characterize the cell-specific role
of TSPO expression in M1 and M2 microglia/macro-
phage after ICH. Though, CD16/32 and CD 206 are
widely used and regarded as signature markers of M1
and M2 microglia/macrophage phenotypes, respect-
ively, the use of a single molecular marker in character-
izing either M1 or M2 microglia/macrophage remains
as a limitation of the study. Further, given the occur-
rence of differential microglia/macrophage phenotypes
after a brain injury, the possibility of expression of
TSPO in other microglia/macrophage phenotypes apart
from M1 and M2 cannot be completely ruled out. Not-
ably, LPS (lipopolysaccharide), a potent ligand of TLR-4
augmented TSPO expression in BV2 microglial cells
[66]. Moreover, in actively proliferating cells and in LPS-
induced cultured retinal microglia, the expression of
TSPO has been observed in the perinuclear and nuclear
area [66, 67]. Consistently, the subcellular localization of
TSPO revealed prominent perinuclear expression after
ICH suggesting a role of TSPO in microglial proliferation
which is often associated with neurodegenerative con-
ditions [68] further emphasizing the therapeutic po-
tential of TSPO. It has been previously reported that
IL-1β and TNF-α can stimulate microglial prolifera-
tion [69–71]. However, the mechanism by which
TSPO regulates neuroinflammation after ICH needs
further investigation.
Further, emerging evidences suggest that the adminis-
tration of TSPO-selective ligands may be useful in the
treatment of neuroinflammatory conditions [72–74] and
may exert neuroprotection after seizures and brain in-
jury by suppressing microglial activation [72, 75–78].
Moreover, minocycline-mediated attenuation of retinal
degeneration was associated with reduction in microglial
reactivity and the expression of TSPO [79]. Notably, the
primary endogenous ligands of TSPO include a polypep-
tide called diazepam-binding inhibitor (DBI) and its
shorter peptide cleavage products called endozepines
[80]. These molecules are expressed and secreted by
glial populations in the CNS [81]. It is postulated that
A
B C
Fig. 10 Genetic knockdown of TSPO augmented hemin-induced release of TNF-α and IL-6. a Genetic knockdown of TSPO in RAW. 264.7 cells
were achieved employing TSPO siRNA as described in the “Methods” section. Genetic knockdown of TSPO significantly augmented the
hemin-induced release of both TNF-α (b) and IL-6 (c) in RAW 264.7 cells. n = 3–4; **p < 0.01 vs. hemin-treated control, ***p < 0.001 vs. control
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the ligand-mediated TSPO signaling in microglia can
increase mitochondrial cholesterol flux, facilitating the
production of modulatory neurosteroids that in turn
repress inflammatory genes in a cell-autonomous man-
ner [66]. Endogenous TSPO signaling may also result
in other physiological changes in microglia including
regulation of calcium influx [82], mitochondrial func-
tion [6], and apoptosis [83], all of which may modulate
microglial activation. However, neither the precise role
of TSPO nor the exact mechanism by which TSPO-
specific ligands confer neuroprotection is known.
Though TSPO ligands have been widely used for brain
imaging of neuroinflammation, in several neuropatho-
logical conditions such as Alzheimer’s disease (AD),
Parkinson’s disease, and Huntington’s disease, no such
imaging technique is currently available to monitor
microglial activation after ICH. The low level of expres-
sion in uninjured brain regions coupled with the injury-
induced remarkable induction makes TSPO a suitable
candidate to monitor inflammation after ICH. Altogether,
the data derived from this study suggest a therapeutic and
diagnostic potential of TSPO after ICH.
Conclusions
The present study reports for the first time that TSPO ex-
pression is found to be increased in the peri-hematomal
brain region 1 to 7 days post-ICH, peaking on day 3 to
day 5 in comparison to sham. Further, the expression of
TSPO is mostly observed in microglia/macrophages sug-
gesting a possible role of TSPO in neuroinflammatory re-
sponse after ICH and this is further supported by its
occurrence in M1 and M2 microglia/macrophage pheno-
types after ICH. Notably, the subcellular localization stud-
ies revealed prominent perinuclear expression of TSPO
after ICH. Though this observation is consistent with the
in vitro studies with cultured microglia [66], the precise
functional significance of TSPO expression in this subcel-
lular area requires further investigation. Moreover, both
genetic and pharmacological studies revealed a regulatory
role of TSPO in the release of pro-inflammatory cytokines
in a macrophage cell line, RAW 264.7. Altogether, the
data suggest that TSPO induction after ICH could be an
intrinsic mechanism to prevent an exacerbated inflamma-
tory response and raise the possibility of targeting TSPO
for the attenuation of secondary brain injury after ICH.
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